The Danish diabetes giant had a good Q3 – witnessing 6% CER sales growth. Ozempic attained blockbuster status, while Novo Nordisk’s much-awaited oral semaglutide (Rybelsus) successfully secured an approval. Although (pricing) erosion of the group’s insulin portfolio has continued.
04 Nov 2019
Steady growth continues, although insulins’ pricing overhang remains
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Steady growth continues, although insulins’ pricing overhang remains
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
04 Nov 2019 -
Author:
Surbhit Gupta -
Pages:
3
The Danish diabetes giant had a good Q3 – witnessing 6% CER sales growth. Ozempic attained blockbuster status, while Novo Nordisk’s much-awaited oral semaglutide (Rybelsus) successfully secured an approval. Although (pricing) erosion of the group’s insulin portfolio has continued.